Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Common Equity (2024 - 2025)

Pelthos Therapeutics has reported Common Equity over the past 2 years, most recently at $38.9 million for Q4 2025.

  • Quarterly results put Common Equity at $38.9 million for Q4 2025, up 1532.61% from a year ago — trailing twelve months through Dec 2025 was $38.9 million (up 1532.61% YoY), and the annual figure for FY2025 was $38.9 million, up 1532.61%.
  • Common Equity for Q4 2025 was $38.9 million at Pelthos Therapeutics, down from $58.3 million in the prior quarter.
  • Over the last five years, Common Equity for PTHS hit a ceiling of $58.3 million in Q3 2025 and a floor of -$6.5 million in Q2 2025.